Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the first part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals explains how predictable, affordable pricing models for FDA-approved oral weight loss drugs can reduce barriers to care, improve long-term adherence, and support better outcomes for patients managing chronic obesity.

Consistent Cash-Pay Options Could Transform Access to Obesity Medications

Podcasts

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence

Articles

By reducing waste, improving forecasting, and strengthening payer negotiations, these  technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

Precision Dosing as a Market Strategy: How Model-Informed Tools Drive Cost, Speed and Access

In the first part of their Pharma Commerce video interview, Boyede Sobitan and Annika Matas of Zebra Technologies warn that ongoing medication shortages are forcing staff to borrow supplies, delay procedures, and divert nurses from patient care to logistical tasks, creating both financial pressures and operational inefficiencies.

How Drug Shortages Could Disrupt Hospital Operations and Strain Patient Care

In the final part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, focuses on physician demand, global momentum, and how US legislation can help the industry finally move beyond paper.

Overcoming Barriers to Full e-Prescribing Adoption

In the second part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, highlights that cutting down on the 90 billion sheets of paper used for medicine inserts each year isn’t just an environmental win—it’s also a critical step toward making drug information more accessible for patients with vision challenges, language barriers, or cognitive and physical disabilities.

Why Reducing Paper Inserts Is About Access as Much as Sustainability

This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.

Pharma Pulse: FDA Approves Sanofi’s Wayrilz, OTC Triptans Show Public Health Gains, and Biosimilar Rules Streamlined

In the first part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, explains how the Prescription Information Modernization Act of 2025 aims to replace package inserts with digital-first documentation, providing patients with better access to understandable medication guidance in the process.

Modernizing Prescription Information 

In the final part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, emphasizes that patient access must remain the top priority, even amid steep tariffs, citing cases like orphan drugs and oncology treatments where government flexibility is essential.

Balancing Tariffs and Patient Access in Pharma Policy

As of today, Aug. 27, wholesale distributors must fully comply with the Drug Supply Chain Security Act’s enhanced drug distribution requirements, closing the FDA’s exemption period and advancing efforts to strengthen patient safety and supply chain integrity.

Patient Support